Monomethyl fumarate

The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.

NICE has recommended Biogen's oral therapy Vumerity (diroximel fumarate) for routine NHS use in patients with relapsing-remitting multiple sclerosis across England, Wales, and Northern Ireland.

The Japanese Ministry of Health, Labour, and Welfare approved Lupkynis (voclosporin) in combination with mycophenolate mofetil for treating lupus nephritis.

The FDA granted full approval to Travere Therapeutics' Filspari (sparsentan) for IgA nephropathy, allowing broader use for patients at risk of disease progression.